# US 10,118,952 B2 · Proteins specific for pyoverdine and pyochelin > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,118,952 B2 - Document ID: US10118952B2 - Status: Granted - Kind: B2 - Application number: 15/727,087 - Filed: 2017-10-06 - Published: 2018-02-08 - Granted: 2018-11-06 - Earliest claimed: 2015-02-18 - Assignees: Sanofi - Applicants: Sanofi - Inventors: Carsten Corvey; Heike Stump; Jochen Kruip; Bernhard Calandra; Astrid Rey; Nathalie Karst; Michael Mourez; Laurent Fraisse; Christine Rothe; Andrea Allersdorfer; Alexander Wiedenmann; Marlon Hinner; Bradley Lunde; Kristian Jensen; Martin Hülsmeyer - Web page: https://patentgrep.com/patent/US10118952B2 ## CPC - C07K 14/4703: {Inhibitors; Suppressors} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)} - A61K 38/012: {from animals} - A61P 5/00: Drugs for disorders of the endocrine system - A61P 31/04: Antibacterial agents - C07K 14/47: from mammals - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins. ## Claims ### Claim 1 A human neutrophil gelatinase-associated lipocalin (hNGAL) mutein polypeptide having binding specificity for pyochelin, wherein the hNGAL mutein comprises 10 or more mutations at positions 36, 40, 41, 45, 46, 49, 52, 65, 68, 70, 72, 73, 77, 79, 81, 87, 100, 103, 106, 125, 127, 132, and 134 of the linear polypeptide sequence of the mature hNGAL (SEQ ID NO: 1). ### Claim 2 (depends on 1) The hNGAL mutein polypeptide e of claim 1, wherein the hNGAL mutein comprises ten or more of the following mutations of SEQ ID NO: 1: L36H, A40Q, I41W, D45G, K46R, Q49R, Y52W, N65D, S68D, L70D, R72A, K73I, D77L, W79R, R81T, C87S, Y100H, L103G, Y106G, K125F, S127I, Y132A, K134F. ### Claim 3 (depends on 1) The hNGAL mutein polypeptide of claim 1, wherein the hNGAL mutein comprises SEQ ID NO: 62. ### Claim 4 (depends on 1) The hNGAL mutein polypeptide of claim 1, wherein the hNGAL mutein is capable of binding pyochelin complexed with iron with a KD of about 200 nM or lower. ### Claim 5 (depends on 1) The hNGAL mutein polypeptide of claim 1, wherein the hNGAL mutein comprises 12 or more mutations at positions 36, 40, 41, 45, 46, 49, 52, 65, 68, 70, 72, 73, 77, 79, 81, 87, 100, 103, 106, 125, 127, 132, and 134 of SEQ ID NO: 1. ### Claim 6 A human neutrophil gelatinase-associated lipocalin (hNGAL) mutein polypeptide having binding specificity for pyochelin, wherein the hNGAL mutein comprises 15 or more mutations at positions 36, 40, 41, 45, 46, 49, 52, 65, 68, 70, 72, 73, 77, 79, 81, 87, 100, 103, 106, 125, 127, 132, and 134 of SEQ ID NO: 1. ### Claim 7 (depends on 6) The hNGAL mutein polypeptide of claim 6, wherein the hNGAL mutein comprises 15 or more of the following mutations of SEQ ID NO: 1: L36H, A40Q, I41W, D45G, K46R, Q49R, Y52W, N65D, S68D, L70D, R72A, K73I, D77L, W79R, R81T, C87S, Y100H, L103G, Y106G, K125F, S127I, Y132A, K134F. ### Claim 8 (depends on 6) The hNGAL mutein polypeptide of claim 6, wherein the hNGAL mutein comprises SEQ ID NO: 62. ### Claim 9 (depends on 6) The hNGAL mutein polypeptide of claim 6, wherein the hNGAL mutein is capable of binding pyochelin complexed with iron with a KD of about 200 nM or lower. ### Claim 10 A human neutrophil gelatinase-associated lipocalin (hNGAL) mutein polypeptide having binding specificity for pyochelin, wherein the hNGAL mutein comprises SEQ ID NO: 62. ### Claim 11 (depends on 10) The hNGAL mutein polypeptide of claim 10, wherein the hNGAL mutein consists of SEQ ID NO: 62. ### Claim 12 (depends on 10) The hNGAL mutein polypeptide of claim 10, wherein the hNGAL mutein is capable of binding pyochelin complexed with iron with a KD of about 200 nM or lower. ### Claim 13 (depends on 1) A composition comprising the hNGAL mutein polypeptide of claim 1, and at least one pharmaceutically acceptable adjuvant, diluent, or carrier. ### Claim 14 (depends on 6) A composition comprising the hNGAL mutein polypeptide of claim 6, and at least one pharmaceutically acceptable adjuvant, diluent, or carrier. ### Claim 15 (depends on 10) A composition comprising the hNGAL mutein polypeptide of claim 10, and at least one pharmaceutically acceptable adjuvant, diluent, or carrier.